The New York Times
A new drug used to treat advanced may also help men if used early in the course of the disease, before an operation, researchers reported Wednesday.
In a small clinical trial, six months of treatment with the drug, Johnson & Johnson’s Zytiga, added to standard therapy, eliminated or nearly eliminated in about one-third of men whose disease had not yet spread beyond the prostate gland but was considered likely to do so.
The exact significance of this must still be determined through larger studies. But researchers said that with and , patients whose tumors are eliminated before an operation, by what is called neoadjuvant , tend to live longer... Read More
Related Information
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
